Who Paid My Doc
Lutathera
Drug Oncology
NDC 69488-003-01
General payments
$30,408,570
Research payments
$38,101,216
Through program year 2025, $30,408,570 in general payments and $38,101,216 in research payments were reported against Lutathera (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $193,517 | 4,839 |
| 2025 | Research | $18,476,589 | 177 |
| 2024 | General | $141,360 | 4,077 |
| 2024 | Research | $17,749,676 | 63 |
| 2023 | General | $8,062,987 | 3,869 |
| 2023 | Research | $1,500,436 | 14 |
| 2022 | General | $5,202,899 | 2,944 |
| 2022 | Research | $52,844 | 11 |
| 2021 | General | $7,667,898 | 2,347 |
| 2021 | Research | $177,212 | 9 |
| 2020 | General | $3,594,083 | 714 |
| 2020 | Research | $144,459 | 20 |
| 2019 | General | $5,545,826 | 77 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 59 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 46 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
18,867 general · 294 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.